
Mustang Bio, Inc.
MBIOHealthcare|Biotechnology|US
$0.39
+0.00 (+0.15%)
DCF Value
$2.93
Tangible Book / Share
$0.98
Cash / Share
$2.12
Financing Filings (last 12 months)
0
No shelf registrations or offering prospectuses filed.
Upcoming Data Readouts (1)
Jul 2027
Est. completion
P1Adult Acute Myeloid Leukemia in Remission
Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
NCT02159495n=31
Awaiting Results (1)
Trials past primary completion date but still active — data readout may be imminent.
Mar 2024
P1P2
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
NCT03277729SEC Filings (52)
Last two years from EDGAR. Insider Form 4s are on the Ownership tab.
| Filed | Form | What it is | Links |
|---|---|---|---|
| Nov 5, 2026 | S-8 | Employee stock plan | DocumentIndex |
| Nov 5, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Oct 15, 2026 | 8-K | Material event | DocumentIndex |
| Aug 5, 2026 | 10-Q | Quarterly report | DocumentIndex |
| May 5, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Apr 17, 2026 | 8-K | Material event | DocumentIndex |
| Mar 19, 2026 | 10-K | Annual report | DocumentIndex |
| Jan 5, 2026 | SC 13D/A | Activist / 5%+ stake | DocumentIndex |
| Dec 23, 2025 | 8-K | Material event | DocumentIndex |
| Dec 3, 2025 | DEF 14A | Proxy / shareholder vote | DocumentIndex |
| Nov 7, 2025 | 10-Q | Quarterly report | DocumentIndex |
| Oct 1, 2025 | SC 13D/A | Activist / 5%+ stake | DocumentIndex |
| Sep 5, 2025 | 424B5 | Offering prospectus | DocumentIndex |
| Aug 12, 2025 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Aug 8, 2025 | 10-Q | Quarterly report | DocumentIndex |
| Jul 9, 2025 | 8-K | Material event | DocumentIndex |
| May 15, 2025 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| May 14, 2025 | 10-Q | Quarterly report | DocumentIndex |
| May 9, 2025 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Apr 11, 2025 | EFFECT | DocumentIndex | |
| Apr 4, 2025 | POS AM | DocumentIndex | |
| Apr 2, 2025 | SC 13D/A | Activist / 5%+ stake | DocumentIndex |
| Apr 1, 2025 | POS EX | DocumentIndex | |
| Apr 1, 2025 | 424B3 | Offering prospectus | DocumentIndex |
| Mar 28, 2025 | 10-K | Annual report | DocumentIndex |
| Mar 5, 2025 | 8-K | Material event | DocumentIndex |
| Mar 3, 2025 | DEF 14C | DocumentIndex | |
| Feb 27, 2025 | 424B3 | Offering prospectus | DocumentIndex |
| Feb 27, 2025 | 8-K | Material event | DocumentIndex |
| Feb 21, 2025 | PRE 14C | DocumentIndex | |
| Feb 21, 2025 | 8-K | Material event | DocumentIndex |
| Feb 14, 2025 | SC 13G | Passive 5%+ stake | DocumentIndex |
| Feb 13, 2025 | 424B3 | Offering prospectus | DocumentIndex |
| Feb 13, 2025 | 8-K | Material event | DocumentIndex |
| Feb 11, 2025 | SC 13G | Passive 5%+ stake | DocumentIndex |
| Feb 11, 2025 | 8-K | Material event | DocumentIndex |
| Feb 7, 2025 | 424B4 | Offering prospectus | DocumentIndex |
| Feb 5, 2025 | EFFECT | DocumentIndex | |
| Feb 5, 2025 | S-1/A | IPO / offering registration | DocumentIndex |
| Jan 22, 2025 | DEF 14C | DocumentIndex |